Identification

Name
Iron
Accession Number
DB01592
Type
Small Molecule
Groups
Approved
Description

A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia.

Structure
Thumb
Synonyms
  • Carbonyl iron
  • Eisen
  • Electrolytic iron
  • Fe
  • fer
  • Ferrum
  • Ferrum metallicum
  • Hierro
  • Iron powder
  • Iron, carbonyl
  • Iron, electrolytic
  • Iron, elemental
  • Iron, reduced
  • Reduced iron
Product Ingredients
IngredientUNIICASInChI Key
Ferrous ascorbateDI3477D0PI24808-52-4RFBYLSCVRUTUSB-ZZMNMWMASA-N
Ferrous fumarateR5L488RY0Q141-01-5PMVSDNDAUGGCCE-TYYBGVCCSA-L
Ferrous gluconate781E2AXH0K299-29-6QDUZQOIJXPPTLY-GMBKLUGCSA-N
Ferrous glycine sulfate56PS9HY5XI14729-84-1YJYOLOWXCPIBSY-UHFFFAOYSA-L
Ferrous succinate818ZYK7N9110030-90-7MDXRFOWKIZPNTA-UHFFFAOYSA-N
Ferrous sulfate2IDP3X9OUD7720-78-7BAUYGSIQEAFULO-UHFFFAOYSA-L
Ferrous sulfate dihydrateG0Z544944910028-21-4KFJBRJOPXNCARV-UHFFFAOYSA-L
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DexironLiquid50 mgIntramuscular; IntravenousLuitpold Pharmaceuticals1996-09-06Not applicableCanada
InfuferLiquid50 mgIntramuscular; IntravenousSandoz Canada Incorporated1997-02-072016-12-01Canada
VenoferLiquid20 mgIntravenousLuitpold Pharmaceuticals2001-06-05Not applicableCanada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ascofer Cap 275mgCapsule33 mgOralDesbergers LtÉe, Division Of Technilab Inc.1974-12-311999-09-17Canada
Chelated Iron 25mg - CapletTablet25 mgOralHealth Wise Nutrition Inc.1995-12-312002-07-18Canada
Chelated Iron Supplement - TabTablet18 mgOralAlbion1996-09-062002-09-30Canada
Fe-chelate TabTablet28 mgOralNutri West Products Ltd.1994-12-311997-08-05Canada
Fera Liq 16.7mg/15mlLiquid16.7 mgOralInno Vite Incorporated1987-12-312007-07-31Canada
Ferinsol DropsSolution / drops125 mgOralMead Johnson Nutritionals1951-12-311996-09-30Canada
Ferion TabTablet65 mgOralPharmetics (2011) Inc.1981-12-312000-08-21Canada
Fero Grad FilmtabTablet, extended release105 mgOralAbbott1961-12-312008-06-06Canada
Ferrous Fumarate Sct Tab 300mgTablet300 mgOralPharmetics (2011) Inc.1978-12-312000-08-21Canada
Ferrous Fumarate Tab 200mgTablet200 mgOralShoppers Drug Mart Inc.1977-12-311998-08-14Canada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ferrous SulfateTablet325 mg/1OralA S Medication Solutions2001-02-19Not applicableUs
Ferrous SulfateElixir220 mg/5mLOralLLC Federal Solutions2013-08-12Not applicableUs
Ferrous SulfateTablet325 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Ferrous SulfateTablet, film coated325 mg/1OralCentral Texas Community Health Centers2014-07-01Not applicableUs
Ferrous SulfateTablet325 mg/1Oralbryant ranch prepack2001-02-19Not applicableUs
Ferrous SulfateTablet, film coated325 mg/1OralSun Pharmaceutical Industries Limited2014-07-01Not applicableUs
Ferrous SulfateTablet325 mg/1OralA S Medication Solutions2001-02-192017-06-20Us
Ferrous SulfateTablet65 mg/1OralBoca Pharmacal, Inc.2010-09-142018-06-30Us
Ferrous SulfateTablet325 mg/1OralUnit Dose Services2001-02-19Not applicableUs
Ferrous SulfateTablet325 mg/1OralRichmond Pharmaceuticals2008-11-05Not applicableUs
International/Other Brands
Ed-In-Sol / Fe-40 / Feosol (GlaxoSmithkline) / Feostat / Fer-In-Sol / Feratab (Upsher-Smith) / Ferate / Fergon / Ferralet / Ferretts / Ferro sanol / Ferro-Caps / Ferro-Time / Ferrousal / Siderol / Simron / Slow Fe / Vitedyn-Slo / Yieronia
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Active FEIron (75 mg/1) + Beta carotene (2100 [iU]/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (1 mg/1) + Cyanocobalamin (30 ug/1) + Folic Acid (1250 ug/1) + Magnesium oxide (30 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (4 mg/1) + Thiamine Hydrochloride (4 mg/1) + Vitamin C (160 mg/1) + Vitamin E (40 [iU]/1) + Zinc oxide (20 mg/1)TabletOralGm Pharmaceuticals2013-11-11Not applicableUs
ActyformIron (4.18 mg) + Copper (1 mg) + Magnesium (61.15 mg) + Zinc (9 mg)CapsuleOralTechnodiet S.E.N.C.1999-10-262008-08-13Canada
Alsimine W Vitamins A DFerrous gluconate (16 mg) + Calcium (13 mg) + Cyanocobalamin (10 mcg) + Dexpanthenol (5 mg) + Dexpanthenol (400 unit) + Nicotinamide (40 mg) + Pyridoxine hydrochloride (3 mg) + Riboflavin 5'-phosphate sodium (2 mg) + Thiamine Hydrochloride (4.5 mg) + Vitamin A (10000 unit)Capsule; LiquidOralAlsi Cie Ltee1978-12-312003-05-21Canada
AppedrineFerrous fumarate (3.33 mg) + Benzocaine (3 mg) + Nicotinamide (3.33 mg) + Riboflavin (.4 mg) + Thiamine Hydrochloride (.33 mg) + Vitamin A (1333 unit) + Sodium ascorbate (10 mg) + Vitamin D (133 unit)TabletOralChattem, Inc.1975-12-312004-07-08Canada
Aurovela 24 FeFerrous fumarate + Ethinyl Estradiol + Norethisterone acetateKitAurobindo Pharma2017-06-15Not applicableUs
AUROVELA FeFerrous fumarate + Ethinyl Estradiol + Norethisterone acetateKitAurobindo Pharma2017-06-15Not applicableUs
Aurovela Fe 1/20Ferrous fumarate + Ethinyl Estradiol + Norethisterone acetateKitAurobindo Pharma2017-06-16Not applicableUs
B Stress C + Iron & ViteFerrous fumarate (27 mg) + Cyanocobalamin (12 mcg) + Folic Acid (.4 mg) + Nicotinamide (100 mg) + Calcium pantothenate (20 mg) + Pyridoxine hydrochloride (25 mg) + Riboflavin (15 mg) + Thiamine mononitrate (15 mg) + Vitamin C (600 mg) + Vitamin E (30 unit)TabletOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1990-12-312004-07-26Canada
BacminFerrous fumarate (27 mg/1) + Biotin (150 ug/1) + Chromium Cr-51 chloride (.1 mg/1) + Cupric oxide (3 mg/1) + Cyanocobalamin (50 ug/1) + Flavone (50 mg/1) + Folic Acid (1 mg/1) + Magnesium oxide (50 mg/1) + Manganese gluconate (5 mg/1) + Nicotinamide (100 mg/1) + Calcium pantothenate (25 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (20 mg/1) + Selenomethionine (50 ug/1) + Thiamine mononitrate (20 mg/1) + Vitamin A acetate (2000 [iU]/1) + Vitamin C (500 mg/1) + Vitamin E acetate (30 [iU]/1) + Zinc oxide (22.5 mg/1)Tablet, coatedOralMarnel Pharmaceuticals, Llc2000-04-01Not applicableUs
Bev 29 TabFerrous gluconate (1 mg) + Biotin (3 mcg) + Choline (63 mg) + Cyanocobalamin (50 mcg) + Folic Acid (.013 mg) + Inositol nicotinate (7 mg) + Niacin (1 mg) + Pantothenic acid (25 mg) + Riboflavin (.025 mg) + Thiamine (10 mg)TabletOralBeverly International Nutrition1987-12-311998-08-01Canada
Categories
UNII
E1UOL152H7
CAS number
7439-89-6
Weight
Average: 55.845
Monoisotopic: 55.934942133
Chemical Formula
Fe
InChI Key
XEEYBQQBJWHFJM-UHFFFAOYSA-N
InChI
InChI=1S/Fe
IUPAC Name
iron
SMILES
[Fe]

Pharmacology

Indication

Used in preventing and treating iron-deficiency anemia.

Structured Indications
Pharmacodynamics

The major activity of supplemental iron is in the prevention and treatment of iron deficiency anemia. Iron has putative immune-enhancing, anticarcinogenic and cognition-enhancing activities.

Mechanism of action

Iron is necessary for the production of hemoglobin. Iron-deficiency can lead to decreased production of hemoglobin and a microcytic, hypochromic anemia.

TargetActionsOrganism
UTransferrin receptor protein 1Not AvailableHuman
UEgl nine homolog 1Not AvailableHuman
UHistone deacetylase 8
cofactor
Human
UAlpha-hemoglobin-stabilizing proteinNot AvailableHuman
UHemoglobin subunit alphaNot AvailableHuman
UFrataxin, mitochondrialNot AvailableHuman
UFerritin heavy chainNot AvailableHuman
UFlap endonuclease 1Not AvailableHuman
UEndonuclease 8-like 1Not AvailableHuman
UEndonuclease 8-like 2Not AvailableHuman
UDNA polymerase betaNot AvailableHuman
UCeruloplasminNot AvailableHuman
USerotransferrinNot AvailableHuman
Absorption

The efficiency of absorption depends on the salt form, the amount administered, the dosing regimen and the size of iron stores. Subjects with normal iron stores absorb 10% to 35% of an iron dose. Those who are iron deficient may absorb up to 95% of an iron dose.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Acute iron overdosage can be divided into four stages. In the first stage, which occurs up to six hours after ingestion, the principal symptoms are vomiting and diarrhea. Other symptoms include hypotension, tachycardia and CNS depression ranging from lethargy to coma. The second phase may occur at 6-24 hours after ingestion and is characterized by a temporary remission. In the third phase, gastrointestinal symptoms recur accompanied by shock, metabolic acidosis, coma, hepatic necrosis and jaundice, hypoglycemia, renal failure and pulmonary edema. The fourth phase may occur several weeks after ingestion and is characterized by gastrointestinal obstruction and liver damage. In a young child, 75 milligrams per kilogram is considered extremely dangerous. A dose of 30 milligrams per kilogram can lead to symptoms of toxicity. Estimates of a lethal dosage range from 180 milligrams per kilogram and upwards. A peak serum iron concentration of five micrograms or more per ml is associated with moderate to severe poisoning in many.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Tyrosine MetabolismMetabolic
Inositol MetabolismMetabolic
Taurine and Hypotaurine MetabolismMetabolic
Pravastatin Action PathwayDrug action
Risedronate Action PathwayDrug action
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)Disease
HypercholesterolemiaDisease
Congenital Bile Acid Synthesis Defect Type IIDisease
Zellweger SyndromeDisease
Congenital Bile Acid Synthesis Defect Type IIIDisease
Refsum DiseaseDisease
Tyrosinemia, transient, of the newbornDisease
Glucose-6-phosphate dehydrogenase deficiencyDisease
Ribose-5-phosphate isomerase deficiencyDisease
Nucleotide Sugars MetabolismMetabolic
Galactose MetabolismMetabolic
Pyrimidine MetabolismMetabolic
Tryptophan MetabolismMetabolic
Retinol MetabolismMetabolic
Alendronate Action PathwayDrug action
Zoledronate Action PathwayDrug action
Tyrosinemia Type IDisease
Cerebrotendinous Xanthomatosis (CTX)Disease
Vitamin A DeficiencyDisease
Hereditary Coproporphyria (HCP)Disease
Disulfiram Action PathwayDrug action
Carnitine SynthesisMetabolic
Galactosemia IIIDisease
Tyrosine hydroxylase deficiencyDisease
Wolman diseaseDisease
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AlmasilateAlmasilate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AloglutamolAloglutamol can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AluminiumAluminium can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AsenapineAsenapine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Iron.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Iron.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Iron.Approved
CefdinirThe serum concentration of Cefdinir can be decreased when it is combined with Iron.Approved
ChlortetracyclineChlortetracycline can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Iron.Approved
CimetidineCimetidine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe serum concentration of Cinoxacin can be decreased when it is combined with Iron.Approved, Investigational, Withdrawn
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Iron.Approved
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Iron.Experimental
DemeclocyclineDemeclocycline can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DexlansoprazoleDexlansoprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DexrabeprazoleDexrabeprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
DimercaprolDimercaprol may increase the nephrotoxic activities of Iron.Approved
Dipotassium phosphateIron can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Iron.Approved
DoxepinDoxepin can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxycyclineDoxycycline can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Iron.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Iron.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Iron.Approved
EnoxacinThe serum concentration of Enoxacin can be decreased when it is combined with Iron.Approved, Investigational
EpinastineEpinastine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EsomeprazoleEsomeprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FamotidineFamotidine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FleroxacinThe serum concentration of Fleroxacin can be decreased when it is combined with Iron.Approved
FlumequineThe serum concentration of Flumequine can be decreased when it is combined with Iron.Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Iron.Approved
GarenoxacinThe serum concentration of Garenoxacin can be decreased when it is combined with Iron.Investigational
GatifloxacinThe serum concentration of Gatifloxacin can be decreased when it is combined with Iron.Approved, Investigational
GemifloxacinThe serum concentration of Gemifloxacin can be decreased when it is combined with Iron.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Iron.Investigational, Withdrawn
HydrotalciteHydrotalcite can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Iron.Investigational
LansoprazoleLansoprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevodopaThe serum concentration of Levodopa can be decreased when it is combined with Iron.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Iron.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Iron.Approved
Lipoic AcidIron can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Iron.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethanthelineMethantheline can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethyldopaThe serum concentration of Methyldopa can be decreased when it is combined with Iron.Approved
MetiamideMetiamide can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MinocyclineMinocycline can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Iron.Approved
Nalidixic AcidThe serum concentration of Nalidixic Acid can be decreased when it is combined with Iron.Approved, Investigational
NemonoxacinThe serum concentration of Nemonoxacin can be decreased when it is combined with Iron.Investigational
NizatidineNizatidine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NorfloxacinThe serum concentration of Norfloxacin can be decreased when it is combined with Iron.Approved
OlanzapineOlanzapine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Iron.Investigational
OmeprazoleOmeprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
Oxolinic acidThe serum concentration of Oxolinic acid can be decreased when it is combined with Iron.Experimental
PancrelipasePancrelipase can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PantoprazolePantoprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PazufloxacinThe serum concentration of Pazufloxacin can be decreased when it is combined with Iron.Investigational
PefloxacinThe serum concentration of Pefloxacin can be decreased when it is combined with Iron.Approved
PenicillamineIron can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Iron.Approved
Pipemidic acidThe serum concentration of Pipemidic acid can be decreased when it is combined with Iron.Experimental
Piromidic acidThe serum concentration of Piromidic acid can be decreased when it is combined with Iron.Experimental
PromethazinePromethazine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PrulifloxacinThe serum concentration of Prulifloxacin can be decreased when it is combined with Iron.Investigational
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Iron.Approved, Investigational
RabeprazoleRabeprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Iron.Approved
RanitidineRanitidine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Iron.Approved
RosoxacinThe serum concentration of Rosoxacin can be decreased when it is combined with Iron.Approved, Investigational
Roxatidine acetateRoxatidine acetate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RufloxacinThe serum concentration of Rufloxacin can be decreased when it is combined with Iron.Experimental
SitafloxacinThe serum concentration of Sitafloxacin can be decreased when it is combined with Iron.Experimental, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium glycerophosphateIron can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateIron can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Iron.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Iron.Approved
TemafloxacinThe serum concentration of Temafloxacin can be decreased when it is combined with Iron.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Iron.Experimental, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Iron.Approved
TriethylenetetramineThe serum concentration of Iron can be decreased when it is combined with Triethylenetetramine.Approved
TromethamineTromethamine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TrovafloxacinThe serum concentration of Trovafloxacin can be decreased when it is combined with Iron.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Iron.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Walter Lugscheider, Paul Mullner, Wilhelm Schiffer, Alois Leutgob, "Arrangement for producing metals, such as molten pig iron, steel pre-material and ferroalloys." U.S. Patent US4617671, issued 0000.

US4617671
General References
Not Available
External Links
Human Metabolome Database
HMDB15531
KEGG Compound
C00023
PubChem Compound
23925
PubChem Substance
46509190
ChemSpider
22368
ChEBI
18248
Therapeutic Targets Database
DAP001313
PharmGKB
PA450087
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Iron
ATC Codes
B03AE01 — Iron, vitamin b12 and folic acidB03AE02 — Iron, multivitamins and folic acidB03AA01 — Ferrous glycine sulfateB03AD02 — Ferrous fumarateB03AA10 — Ferrous ascorbateB03AA02 — Ferrous fumarateA11AA01 — Multivitamins and ironB03AE03 — Iron and multivitaminsB03AE04 — Iron, multivitamins and mineralsB03AA03 — Ferrous gluconateB03AA06 — Ferrous succinate
AHFS Codes
  • 20:04.00 — Antianemia Drugs
  • 20:04.04 — Iron Preparations
  • 88:29.00* — Minerals
FDA label
Download (100 KB)
MSDS
Download (75.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentIron Deficiency Anemia of Pregnancy1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceIron-Deficiency Anemias / Kidney Failure,Chronic1
1CompletedPreventionBacterial Infection Due to Helicobacter Pylori (H. Pylori) / Healthy Participants / Non-anemic Children1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentIron-refractory, Iron-deficiency Anemia (IRIDA)1
1, 2Not Yet RecruitingPreventionPrevention of Anemia1
2Active Not RecruitingTreatmentIron-Refractory Iron-Deficiency Anemia1
2CompletedTreatmentAnemias2
2CompletedTreatmentAngiodysplasia / Gastric Antral Vascular Ectasia / Obscure Gastrointestinal Bleeding / Thalidomide1
2CompletedTreatmentAutism Spectrum Conditions/Disorders / Sleeplessness1
2CompletedTreatmentChronic Arsenic Poisoning1
2CompletedTreatmentChronic Kidney Disease (CKD)1
2RecruitingSupportive CareMetastatic Colorectal Cancers1
2RecruitingTreatmentAnemias / Congenital Heart Disease (CHD) / Cyanosis / Cyanotic Congenital Heart Disease1
2RecruitingTreatmentIron Deficiency Anemia (IDA) / Restless Legs Syndrome (RLS)1
2RecruitingTreatmentIron-Deficiency Anemias1
2Unknown StatusPreventionLead Toxicity1
2Unknown StatusTreatmentAnemias1
2WithdrawnTreatmentInflammatory Bowel Diseases (IBD) / Iron Deficiency Anemia (IDA)1
2, 3CompletedTreatmentHaematological Malignancies1
2, 3CompletedTreatmentHeart Failure, Systolic / Iron-Deficiency Anemias1
2, 3CompletedTreatmentIron Deficiency Anemia (IDA)1
2, 3TerminatedTreatmentIron-Deficiency Anemias / Postpartum Depression / Puerperal Disorders1
3Active Not RecruitingTreatmentFibromyalgia, Primary1
3CompletedNot AvailableAnemias / Haematopoiesis1
3CompletedDiagnosticAnemias1
3CompletedOtherChronic Kidney Disease (CKD)1
3CompletedPreventionIron Deficiency1
3CompletedSupportive CareAnemias / Postoperative Blood Loss1
3CompletedTreatmentAnemias5
3CompletedTreatmentChronic Kidney Disease (CKD) / Iron Deficiency Anemia (IDA)1
3CompletedTreatmentHip Fractures1
3CompletedTreatmentIron Deficiency1
3CompletedTreatmentIron Deficiency Anemia (IDA)2
3CompletedTreatmentIron-Deficiency Anemias / Obese experiencing rapid weight loss1
3CompletedTreatmentPostpartum Anemia1
3CompletedTreatmentUterine Leiomyomas1
3RecruitingTreatmentAnemias5
3RecruitingTreatmentCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD) / Iron-Deficiency Anemias1
3TerminatedPreventionContraception1
3TerminatedTreatmentIron Deficiency Anemia (IDA)1
3TerminatedTreatmentIron Deficiency Anemia (IDA) / Nondialysis Dependent Chronic Kidney Disease / Nondialysis-dependent chronic kidney disease1
3WithdrawnTreatmentLeiomyomas1
4Active Not RecruitingTreatmentIron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass1
4CompletedTreatmentAnemias1
4CompletedTreatmentAnemias / Hemorrhage, Gastrointestinal1
4CompletedTreatmentAnemias / Neoplasms, Colorectal1
4CompletedTreatmentCrohn's Disease (CD) / Ulcerative Colitis (UC)1
4CompletedTreatmentHyperemesis Gravidarum / Morning Sickness / Nausea / Pregnancy / Vomiting1
4CompletedTreatmentIron Deficiency / Tiredness1
4CompletedTreatmentIron-Deficiency Anemias / Kidney Failure,Chronic2
4CompletedTreatmentKnee Osteoarthritis (Knee OA) / Postoperative Anaemia1
4CompletedTreatmentLiposomated Iron / Parenteral Iron Therapy / Y-de-Roux Gastric By-Pass1
4CompletedTreatmentPregnancy1
4Enrolling by InvitationDiagnosticIron Absorption / Post-gastrointestinal bypass surgery / Roux- en -y Gastric Bypass1
4Enrolling by InvitationTreatmentIron Deficiency1
4Not Yet RecruitingTreatmentAnemias / Major Abdominal Surgery / Pre-operative1
4RecruitingSupportive CareIron Deficiency1
4RecruitingTreatmentAnemia During Pregnancy1
4RecruitingTreatmentAnemias / Carcinoma, Colorectal / General Surgery1
4RecruitingTreatmentAnemias / Hematopoietic Stem Cell Transplantation (HSCT) / Malignant Lymphomas1
4RecruitingTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF) / Iron Deficiency1
4RecruitingTreatmentIron Deficiency Anemia (IDA)1
4RecruitingTreatmentIron-Deficiency Anemias1
4RecruitingTreatmentLeiomyomas1
4TerminatedTreatmentChronic Kidney Disease (CKD) / Iron-Deficiency Anemias1
4TerminatedTreatmentLymphoid Disease / Solid Cancer Metastatic Disease1
4Unknown StatusPreventionAnemias / Child Behavior Disorders / Cognitive Manifestations / Iron-Deficiency1
4Unknown StatusTreatmentAnemias1
4Unknown StatusTreatmentAnemias / Iron Deficiency1
4Unknown StatusTreatmentIron Deficiency Anemia (IDA)1
4Unknown StatusTreatmentIron Deficiency Anemia (IDA) / Neoplasms, Colorectal1
4Unknown StatusTreatmentPostoperative Anaemia1
4WithdrawnTreatmentIron Deficiency1
Not AvailableCompletedNot AvailableAnemias1
Not AvailableCompletedNot AvailableAnemias / Iron Deficiency / Plasmodium Infections / Schistosomiasis Infection1
Not AvailableCompletedBasic ScienceCardiovascular Disease (CVD)1
Not AvailableCompletedBasic ScienceCritical Illness1
Not AvailableCompletedBasic ScienceIron Bioavailability1
Not AvailableCompletedDiagnosticHFE-Associated Hereditary Hemochromatosis / Myocardial Iron Overload1
Not AvailableCompletedPreventionAnaemia in Children1
Not AvailableCompletedPreventionIron Metabolic Homeostasis1
Not AvailableCompletedPreventionPostpartum Anemia1
Not AvailableCompletedPreventionVisceral Leishmaniasis1
Not AvailableCompletedTreatmentAnemias1
Not AvailableCompletedTreatmentAnemias / Helminthiases / Schistosoma infection1
Not AvailableCompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori) / Children / Iron Deficiency Anemia (IDA) / No Systemic Infection / Not Severely Malnourished1
Not AvailableCompletedTreatmentCrohn's Disease (CD)1
Not AvailableCompletedTreatmentCystic Fibrosis (CF) / Iron-Deficiency Anemias1
Not AvailableCompletedTreatmentVulvovaginal Candidiasis1
Not AvailableNot Yet RecruitingPreventionAnemias / Hip Fractures1
Not AvailableNot Yet RecruitingTreatmentComplex Valvular Heart Surgery1
Not AvailableNot Yet RecruitingTreatmentCraniosynostosis1
Not AvailableRecruitingDiagnosticIron Absorption1
Not AvailableRecruitingTreatmentAnemia in Pregnancy1
Not AvailableRecruitingTreatmentAnemias / Chronic Kidney Disease (CKD) / Iron Deficiency1
Not AvailableRecruitingTreatmentEPP / Protoporphyria, Erythropoietic / X-Linked Protoporphyria / XLP1
Not AvailableRecruitingTreatmentHereditary Haemorrhagic Telangiectasia (HHT)1
Not AvailableTerminatedPreventionAnemias / Plasmodium Infections1
Not AvailableUnknown StatusTreatmentAnemias / Hemorrhage1
Not AvailableUnknown StatusTreatmentHealthy Volunteers1
Not AvailableUnknown StatusTreatmentRenal Failure Chronic Requiring Hemodialysis1
Not AvailableWithdrawnPreventionAnemias1
Not AvailableWithdrawnPreventionEndometriotic Cysts1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Capsule; liquidOral
CapsuleOral33 mg
TabletOral25 mg
TabletOral18 mg
Capsule, liquid filledOral
CapsuleOral
LiquidIntramuscular; Intravenous50 mg
Tablet, chewableOral
LotionTopical
TabletOral28 mg
LiquidOral16.7 mg
Solution / dropsOral125 mg
TabletOral65 mg
Tablet, extended releaseOral
Tablet, extended releaseOral105 mg
TabletOral200 mg
ElixirOral220 mg/5mL
TabletOral325 mg/1
TabletOral65 mg/1
Tablet, film coatedOral325 mg/1
TabletOral325 mg
SyrupOral35 mg
SyrupOral
Capsule, extended releaseOral30 mg
CapsuleOral150 mg/1
CapsuleOral40 mg
TabletOral30 mg
Tablet, extended releaseOral35 mg
TabletOral37 mg
CapsuleOral50 mg
Tablet, extended releaseOral50 mg
Tablet, chewableOral15 mg/1
TabletOral35 mg
Tablet, effervescentOral
TabletOral6 mg
Liquid; tabletOral
LiquidOral
Solution / dropsOral
SolutionOral
Tablet, delayed releaseOral300 mg
TabletOral300 mg
TabletOral
Tablet, film coatedOral
Kit
PowderOral
CapsuleOral100 mg
Capsule, gelatin coatedOral
Tablet, delayed releaseOral60 mg
LiquidIntravenous20 mg
Tablet, coatedOral
Prices
Unit descriptionCostUnit
Iron chews 15 mg tablet chew0.29USD tablet
Ferrous sulfate 28 mg tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)1538 °CNot Available
Predicted Properties
PropertyValueSource
logP-0.77ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9838
Blood Brain Barrier+0.9733
Caco-2 permeable+0.7354
P-glycoprotein substrateNon-substrate0.885
P-glycoprotein inhibitor INon-inhibitor0.9787
P-glycoprotein inhibitor IINon-inhibitor0.9858
Renal organic cation transporterNon-inhibitor0.9108
CYP450 2C9 substrateNon-substrate0.8466
CYP450 2D6 substrateNon-substrate0.8259
CYP450 3A4 substrateNon-substrate0.8158
CYP450 1A2 substrateNon-inhibitor0.8807
CYP450 2C9 inhibitorNon-inhibitor0.9373
CYP450 2D6 inhibitorNon-inhibitor0.9708
CYP450 2C19 inhibitorNon-inhibitor0.9553
CYP450 3A4 inhibitorNon-inhibitor0.988
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.882
Ames testNon AMES toxic0.9633
CarcinogenicityCarcinogens 0.664
BiodegradationReady biodegradable0.7326
Rat acute toxicity2.0135 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9547
hERG inhibition (predictor II)Non-inhibitor0.9746
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as homogeneous transition metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a transition metal atom.
Kingdom
Inorganic compounds
Super Class
Homogeneous metal compounds
Class
Homogeneous transition metal compounds
Sub Class
Not Available
Direct Parent
Homogeneous transition metal compounds
Alternative Parents
Not Available
Substituents
Homogeneous transition metal
Molecular Framework
Not Available
External Descriptors
elemental iron (CHEBI:82664)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Virus receptor activity
Specific Function
Cellular uptake of iron occurs via receptor-mediated endocytosis of ligand-occupied transferrin receptor into specialized endosomes. Endosomal acidification leads to iron release. The apotransferri...
Gene Name
TFRC
Uniprot ID
P02786
Uniprot Name
Transferrin receptor protein 1
Molecular Weight
84870.665 Da
References
  1. Hemadi M, Ha-Duong NT, El Hage Chahine JM: The mechanism of iron release from the transferrin-receptor 1 adduct. J Mol Biol. 2006 May 12;358(4):1125-36. Epub 2006 Mar 13. [PubMed:16564538]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Peptidyl-proline dioxygenase activity
Specific Function
Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific prol...
Gene Name
EGLN1
Uniprot ID
Q9GZT9
Uniprot Name
Egl nine homolog 1
Molecular Weight
46020.585 Da
References
  1. Davidson TL, Chen H, Di Toro DM, D'Angelo G, Costa M: Soluble nickel inhibits HIF-prolyl-hydroxylases creating persistent hypoxic signaling in A549 cells. Mol Carcinog. 2006 Jul;45(7):479-89. [PubMed:16649251]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Cofactor
General Function
Transcription factor binding
Specific Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
Gene Name
HDAC8
Uniprot ID
Q9BY41
Uniprot Name
Histone deacetylase 8
Molecular Weight
41757.29 Da
References
  1. Gantt SL, Gattis SG, Fierke CA: Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion. Biochemistry. 2006 May 16;45(19):6170-8. [PubMed:16681389]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Acts as a chaperone to prevent the harmful aggregation of alpha-hemoglobin during normal erythroid cell development. Specifically protects free alpha-hemoglobin from precipitation. It is predicted to modulate pathological states of alpha-hemoglobin excess such as beta-thalassemia.
Specific Function
Hemoglobin binding
Gene Name
AHSP
Uniprot ID
Q9NZD4
Uniprot Name
Alpha-hemoglobin-stabilizing protein
Molecular Weight
11840.325 Da
References
  1. Zhou S, Olson JS, Fabian M, Weiss MJ, Gow AJ: Biochemical fates of alpha hemoglobin bound to alpha hemoglobin-stabilizing protein AHSP. J Biol Chem. 2006 Oct 27;281(43):32611-8. Epub 2006 Aug 10. [PubMed:16901899]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Oxygen transporter activity
Specific Function
Involved in oxygen transport from the lung to the various peripheral tissues.
Gene Name
HBA1
Uniprot ID
P69905
Uniprot Name
Hemoglobin subunit alpha
Molecular Weight
15257.405 Da
References
  1. Zhou S, Olson JS, Fabian M, Weiss MJ, Gow AJ: Biochemical fates of alpha hemoglobin bound to alpha hemoglobin-stabilizing protein AHSP. J Biol Chem. 2006 Oct 27;281(43):32611-8. Epub 2006 Aug 10. [PubMed:16901899]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Promotes the biosynthesis of heme and assembly and repair of iron-sulfur clusters by delivering Fe(2+) to proteins involved in these pathways. May play a role in the protection against iron-catalyzed oxidative stress through its ability to catalyze the oxidation of Fe(2+) to Fe(3+); the oligomeric form but not the monomeric form has in vitro ferroxidase activity. May be able to store large amounts of iron in the form of a ferrihydrite mineral by oligomerization; however, the physiological relevance is unsure as reports are conflicting and the function has only been shown using heterologous overexpression systems. Modulates the RNA-binding activity of ACO1.
Specific Function
2 iron, 2 sulfur cluster binding
Gene Name
FXN
Uniprot ID
Q16595
Uniprot Name
Frataxin, mitochondrial
Molecular Weight
23134.895 Da
References
  1. Bencze KZ, Kondapalli KC, Cook JD, McMahon S, Millan-Pacheco C, Pastor N, Stemmler TL: The structure and function of frataxin. Crit Rev Biochem Mol Biol. 2006 Sep-Oct;41(5):269-91. [PubMed:16911956]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Iron ion binding
Specific Function
Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Has ferroxidase activity. Iron is taken up in the ferrous form and deposited as ferric hydroxides after ...
Gene Name
FTH1
Uniprot ID
P02794
Uniprot Name
Ferritin heavy chain
Molecular Weight
21225.47 Da
References
  1. Toussaint L, Bertrand L, Hue L, Crichton RR, Declercq JP: High-resolution X-ray structures of human apoferritin H-chain mutants correlated with their activity and metal-binding sites. J Mol Biol. 2007 Jan 12;365(2):440-52. Epub 2006 Oct 7. [PubMed:17070541]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Structure-specific nuclease with 5'-flap endonuclease and 5'-3' exonuclease activities involved in DNA replication and repair. During DNA replication, cleaves the 5'-overhanging flap structure that is generated by displacement synthesis when DNA polymerase encounters the 5'-end of a downstream Okazaki fragment. It enters the flap from the 5'-end and then tracks to cleave the flap base, leaving a nick for ligation. Also involved in the long patch base excision repair (LP-BER) pathway, by cleaving within the apurinic/apyrimidinic (AP) site-terminated flap. Acts as a genome stabilization factor that prevents flaps from equilibrating into structurs that lead to duplications and deletions. Also possesses 5'-3' exonuclease activity on nicked or gapped double-stranded DNA, and exhibits RNase H activity. Also involved in replication and repair of rDNA and in repairing mitochondrial DNA.
Specific Function
5'-3' exonuclease activity
Gene Name
FEN1
Uniprot ID
P39748
Uniprot Name
Flap endonuclease 1
Molecular Weight
42592.635 Da
References
  1. Hegde ML, Hegde PM, Holthauzen LM, Hazra TK, Rao KS, Mitra S: Specific Inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential etiological linkage to neurodegenerative diseases. J Biol Chem. 2010 Sep 10;285(37):28812-25. doi: 10.1074/jbc.M110.126664. Epub 2010 Jul 9. [PubMed:20622253]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Not Available
Gene Name
NEIL1
Uniprot ID
Q96FI4
Uniprot Name
Endonuclease 8-like 1
Molecular Weight
43683.625 Da
References
  1. Hegde ML, Hegde PM, Holthauzen LM, Hazra TK, Rao KS, Mitra S: Specific Inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential etiological linkage to neurodegenerative diseases. J Biol Chem. 2010 Sep 10;285(37):28812-25. doi: 10.1074/jbc.M110.126664. Epub 2010 Jul 9. [PubMed:20622253]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Involved in base excision repair of DNA damaged by oxidation or by mutagenic agents. Has DNA glycosylase activity towards 5-hydroxyuracil and other oxidized derivatives of cytosine with a preferenc...
Gene Name
NEIL2
Uniprot ID
Q969S2
Uniprot Name
Endonuclease 8-like 2
Molecular Weight
36826.285 Da
References
  1. Hegde ML, Hegde PM, Holthauzen LM, Hazra TK, Rao KS, Mitra S: Specific Inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential etiological linkage to neurodegenerative diseases. J Biol Chem. 2010 Sep 10;285(37):28812-25. doi: 10.1074/jbc.M110.126664. Epub 2010 Jul 9. [PubMed:20622253]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Microtubule binding
Specific Function
Repair polymerase that plays a key role in base-excision repair. Has 5'-deoxyribose-5-phosphate lyase (dRP lyase) activity that removes the 5' sugar phosphate and also acts as a DNA polymerase that...
Gene Name
POLB
Uniprot ID
P06746
Uniprot Name
DNA polymerase beta
Molecular Weight
38177.34 Da
References
  1. Hegde ML, Hegde PM, Holthauzen LM, Hazra TK, Rao KS, Mitra S: Specific Inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential etiological linkage to neurodegenerative diseases. J Biol Chem. 2010 Sep 10;285(37):28812-25. doi: 10.1074/jbc.M110.126664. Epub 2010 Jul 9. [PubMed:20622253]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ferroxidase activity
Specific Function
Ceruloplasmin is a blue, copper-binding (6-7 atoms per molecule) glycoprotein. It has ferroxidase activity oxidizing Fe(2+) to Fe(3+) without releasing radical oxygen species. It is involved in iro...
Gene Name
CP
Uniprot ID
P00450
Uniprot Name
Ceruloplasmin
Molecular Weight
122204.45 Da
References
  1. Ha-Duong NT, Eid C, Hemadi M, El Hage Chahine JM: In vitro interaction between ceruloplasmin and human serum transferrin. Biochemistry. 2010 Dec 7;49(48):10261-3. doi: 10.1021/bi1014503. Epub 2010 Nov 9. [PubMed:21049900]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transferrin receptor binding
Specific Function
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from si...
Gene Name
TF
Uniprot ID
P02787
Uniprot Name
Serotransferrin
Molecular Weight
77063.195 Da
References
  1. Ha-Duong NT, Eid C, Hemadi M, El Hage Chahine JM: In vitro interaction between ceruloplasmin and human serum transferrin. Biochemistry. 2010 Dec 7;49(48):10261-3. doi: 10.1021/bi1014503. Epub 2010 Nov 9. [PubMed:21049900]

Drug created on August 29, 2007 10:01 / Updated on November 23, 2017 11:20